Anti-SLC9A7 antibody produced in rabbit

Solute carrier family 9 member 7 (SLC9A7), also called sodium/hydrogen exchanger 7 (NHE7), is a 80 kDa protein present in trans-Golgi complex. It is a sodium/hydrogen exchanger with N-terminal membrane spanning region and C-terminal hydrophilic tail. SLC9A7 is mapped to human chromosome Xp11.3.

solute carrier family 9, subfamily A (NHE7, cation proton antiporter 7), member 7 recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

Solute carrier family 9 member 7 (SLC9A7) maintains cation homeostasis in trans-Golgi. Its interaction with secretory carrier membrane protein (SCAMP) is crucial for regulating transport in the trans-Golgi complex. SLC9A7 functions like vacuolar (H+)-ATPases (V-ATPases), as a proton-loading transporter. SLC9A7 is highly is expressed in breast cancer and contributes to tumor progression. Polymorphisms in the SLC9A7 gene may contribute to pathogenesis of Alzheimer′s disease. Missense mutation in SLC9A7 is also implicated with metabolic disorder,cystinuria. Deletion of SLC9A7 gene is implicated X-linked disorder, resulting in mental retardation.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide.

Corresponding Antigen APREST84427

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany